A single master protocol is now grouping multiple experimental drug studies for rare pediatric, adolescent, and young adult sarcomas under a single shared infrastructure. The approach is designed to overcome the trial-recruitment barriers that have long stalled drug development for these ultra-rare cancers, according to an editorial published in Tumori Journal.
The platform, called OCTOPUS, targets non-rhabdomyosarcoma soft tissue sarcomas, which is a group of more than 50 distinct tumor subtypes that together make up roughly 4% to 5% of childhood cancers.
Challenges in Treating NRSTS
NRSTS were once managed as a single, broad disease category with a uniform treatment approach, but care is now moving toward therapy tailored to specific histologic subtypes and, in some cases, to molecular subgroups.
Implementation of these treatments is clearly limited by the extreme rarity of each individual histotype, the authors wrote. Due to the low numbers, conducting clinical trials for NRSTS has been difficult, and international programs are essential.
Rarity of NRSTS subtypes has stalled clinical trial progress, with two prior international studies establishing the current risk-adapted standards of care for NRSTS, but those standards leave real gaps: survival rates remain poor for high‑risk disease, and no standard of care exists once a tumor becomes metastatic, progresses, or returns.
The OCTOPUS Platform
The OCTOPUS platform extends the trend of closing diagnostic and treatment gaps in pediatric STS by building a single legal and operational structure through shared case report forms, a translational research pipeline, and a network of coordinating centers.
Through this platform, individual subtrials for specific histotypes or molecular subgroups can open faster and share infrastructure, with patients who aren’t eligible for an open subtrial tracked in a real‑world data registry called SARC.
Related: User Blocked After Violating Platform Policies
The registry function points to one of the platform’s more consequential design choices for payers and health technology assessment bodies, as HTA agencies have struggled to evaluate the cost‑effectiveness of tumor‑agnostic compounds due to a lack of comparable standard‑of‑care data.
OCTOPUS team members have already opened early discussions with the European Medicines Agency, the FDA, and HTA bodies to ensure the registry and subtrial data will be usable for registration and reimbursement decisions, not just for research purposes.
Success of the OCTOPUS platform will depend on its ability to generate high‑quality, real‑world data that can be used to support regulatory decisions, and the platform’s designers are taking a cautious approach to ensuring that the data collected will be usable for registration and reimbursement decisions.
Designers are also pushing for cross‑age collaboration, arguing that adolescents and young adults with sarcoma have historically fallen between pediatric and adult trial networks, and subtrials will be built around molecular targets and mechanism of action rather than strict age cutoffs.
International sponsorship for OCTOPUS and its subtrials is being coordinated by the Princess Máxima Center for Pediatric Oncology in the Netherlands, and the platform is linked to a companion molecular diagnostic study, MyKids, intended to feed preclinical findings back into trial design.
The model’s impact on the path to approved therapies for these ultra‑rare cancers will depend in part on how regulators and payers ultimately treat the registry data the platform is built to generate, and the authors conclude that the multi‑stakeholder initiative will ultimately improve access to innovative therapies for patients with ultra‑rare sarcomas.
Patients with cancer may benefit from cancer drug research.
